Relation between paraoxonase activity, other HDL components and inflammatory conditions in hemodialyzed patients;Relacion entre paraoxonasa, otros componentes de HDL y estado inflamatorio en hemodialisis

Medicina

Volumn 70, Issue 6, 2010, Pages 508-512

  Gonzalez, Ana Ines ^a   Brites, Fernando ^a   Elbert, Alicia ^b   Gomez Rosso, Leonardo ^a   Berg, Gabriela ^a   Wikinski, Regina ^a   Schreier, Laura ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b CEREHA Centro de Enfermedades Renales e Hipertensión Arterial   (Argentina)

Author keywords

HDL; Hemodialysis; Inflammation; Lipoproteins; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; NEPHRITIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; INFLAMMATION; MIDDLE AGED; REFERENCE VALUE; RENAL REPLACEMENT THERAPY;

ADULT; AGED; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; REFERENCE VALUES; RENAL DIALYSIS;

EID: 78650675128     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cusumano A, Garcia Garcia G, Gonzalez Bedat C. The Latin-American Dialysis and Transplant Registry: Report 2006. Ethn Dis 2009; 19 (Suppl 1): S3-6.
2. González AI, Schreier L, Elbert A, et al. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients. Metabolism 2003; 52: 116-21.
3. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61: 209-18.
4. Ajani U, Ford E, Mokdad A. Prevalence of high C-Reactive Protein in persons with serum lipid concentrations within recommended values. Clin Chem 2004; 50: 1618-22.
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002: 347: 1557-65.
6. Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
7. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-54.
8. Himmelfarb J. Oxidative stress in hemodialysis. Contrib Nephrol 2008; 161: 132-7.
9. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998; 9: 319-24.
10. Soran H, Younis N, Charlton-Menys V, Durrington P. Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol 2009; 20: 265-74.
11. Aviram M, Rosemblat M. Paraoxonases 1, 2 and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004; 37: 1304-16.
12. Brites FD, Verona J, Schreier LE, Fruchart JC, Castro GR, Wikinski RL. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 2004; 35: 235-40.
13. Suehiro T, Ikeda Y, Shiinoki T, et al. Serum paraoxonase concentration in patients undergoing hemodialysis. J Atheroscler Tromb 2002; 9: 133-8.
14. Sanguinetti S, Brites F, Fasulo V, et al. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. Diab Nutr Metab 2001; 14: 27-36.
15. Kidney Disease Outcomes Quality Initiative Group, National Kidney Foundation. Clinical practice guidelines for managing dyslipemias in chronic kidney disease. Am J Kidney Dis 2003; 4 Suppl 3: S1-91.
16. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III), National Cholesterol Education Program. Executive Summary of the Third Report. JAMA 2001; 285: 2486-97.
17. Kopple JD. The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr 2005; 81: 1257-66.
18. Rasouli N, Ken PA. Adipocitokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93 (Suppl 1): S64-73.
19. Navab M, Reddy S, Van Lenten B, Anantharamaiah G, Fogelman A. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; S145-9.
20. Van Lenten B, Hama S, de Beer F, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Lost of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.
21. Kaysen GA. Disorders in high-density metabolism with insulin resistance and chronic renal disease. J Ren Nutr 2007; 17: 4-8.
22. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427-34.
23. Jurek A, Turyna B, Kubit P, Klein A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 2006; 39: 19-27.
24. Ece A, Atamer Y, Gürkan F, et al. Paraoxonase, anti-oxidant response and oxidative stress in children with chronic renal failure. Pediatr Nephrol 2006; 21: 239-245.
25. Moradi H, Pahl M, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Traslational Res 2009; 153: 77-85.
26. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON 1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 2008; 12: 471-9.
27. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic renal disease. Kidney Int 2004; 64: 1009-16.
28. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paroxonase 1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006; 186: 396-401.